MetaCap

20/20 Biolabs (AIDX) vs UL Solutions (ULS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

UL Solutions is the larger company by market cap ($14.67 billion vs $2.2 million), about 6672.0 times the size, while 20/20 Biolabs is growing revenue faster (+16.7% vs +6.4%). UL Solutions pays a dividend yielding 0.78%, while 20/20 Biolabs does not currently pay one. UL Solutions converts more of its revenue into profit, with a net margin of 10.6% versus -182.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AIDX-54.26%ULS+8.21%
+25%-16%-58%
Oct 7, 20261 yearNov 20, 2026
AIDX-58.11%ULS+3.79%
+18%-22%-62%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AIDX versus ULS key metrics
MetricAIDXULS
Share price$0.1571$72.64
Market cap$2.20M$14.67B
1-day change-13.49%-2.99%
YTD return—-7.89%
1-year return—-15.24%
P/E ratio (TTM)—28.83
Forward P/E—27.49
EPS (TTM)$-0.75$2.52
Dividend yield0.00%0.78%
Annual dividend$0.00$0.565
Revenue (latest FY)$2.05M$3.05B
Revenue growth (YoY)+16.71%+6.38%
Net income (latest FY)$-3.74M$325.00M
Gross margin29.56%49.46%
Operating margin-162.87%17.10%
Net margin-182.82%10.65%
52-week high$50.00$107.54
52-week low$0.1556$63.17
Distance from 52-week high-99.69%-32.45%
Analyst consensusnonebuy
Avg. price target upside+3082.69%+32.78%
Average volume139.24K873.95K
Shares outstanding13.99M78.15M
Employees414,587
SectorHealth CareHealth Care
IndustryPrecision InstrumentsPrecision Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • UL Solutions is about 6672.0 times larger than 20/20 Biolabs by market value ($14.67B vs $2.20M).
  • UL Solutions is more profitable, keeping 10.6 cents of every revenue dollar as net income versus -182.8 cents for 20/20 Biolabs.
  • 20/20 Biolabs grew revenue faster in its latest fiscal year (+16.71% vs +6.38%).

About 20/20 Biolabs

AIDX stock →

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases.

Health Care · Precision Instruments · 4 employees

About UL Solutions

ULS stock →

UL Solutions Inc., together with its subsidiaries, provides testing, inspection and certification services and related software and advisory services worldwide. It operates through three segments: Industrial, Consumer, and Software and Advisory.

Health Care · Precision Instruments · 14,587 employees

AIDX vs ULS FAQ

Which is bigger, 20/20 Biolabs or UL Solutions?

UL Solutions (ULS) is larger, with a market capitalization of $14.67B compared with $2.20M for 20/20 Biolabs (AIDX).

Which pays a higher dividend, 20/20 Biolabs or UL Solutions?

UL Solutions pays a dividend yielding 0.78%, while 20/20 Biolabs does not currently pay a regular dividend.

Are 20/20 Biolabs and UL Solutions in the same industry?

Yes. Both are classified in the Precision Instruments industry within the Health Care sector.

More comparisons